Effect of Clopidogrel and Ticlopidine on Cytochrome P450 2B6 Activity as Measured by Bupropion Hydroxylation

@article{Turpeinen2005EffectOC,
  title={Effect of Clopidogrel and Ticlopidine on Cytochrome P450 2B6 Activity as Measured by Bupropion Hydroxylation},
  author={Miia Turpeinen and Ari Tolonen and Jouko Uusitalo and Jorma E. Jalonen and Olavi Pelkonen and Kari Laine},
  journal={Clinical Pharmacology \& Therapeutics},
  year={2005},
  volume={77}
}
Interactions of tizanidine with CYP1A2 enzyme inhibitors : Studies in vitro and in humans
TLDR
This dissertation aims to demonstrate the efforts towards in-situ applicability of EMMARM, as to provide real-time information about thehardt's disease and its effects on the immune system.
CYP2B: 2B or Not 2B?
This chapter discusses the genetics, metabolic actions, substrates, inducers, and inhibitors of cytochrome P450 2B6.
Measurement of In Vitro Cytochrome P450 2B6 Activity
TLDR
This assay allows the use of very low concentrations of human liver microsomes or recombinant enzyme, and it represents a selective, sensitive approach to assessing in vitro CYP2B6 activity, with minimal sample preparation.
Cytochrome P450 2B6: function, genetics, and clinical relevance
TLDR
CYP2B6 is one of the most polymorphic CYP genes in humans with over 100 described SNPs, numerous complex haplotypes and distinct ethnic and racial frequencies and the main characteristics of clinical relevance are summarized.
Prasugrel, a New Thienopyridine Antiplatelet Drug, Weakly Inhibits Cytochrome P450 2B6 in Humans
TLDR
The results of this open‐label, multiple‐dose, 2‐period, fixed‐sequence study assessed CYP2B6 inhibition by prasugrel using bupropion as a probe substrate, where its active metabolite, hydroxybupropion, is almost exclusively formed by CYP 2B6.
Dissecting the Activation of Thienopyridines by Cytochromes P450 Using a Pharmacodynamic Assay In Vitro
  • L. Abell, E. Liu
  • Biology, Chemistry
    Journal of Pharmacology and Experimental Therapeutics
  • 2011
TLDR
These studies show that, in vitro, CYP3A4/5, 2C19, and 2B6 are individually capable of converting clopidogrel and prasugrel to the AM and that the cytochrome P450 preference for these two thienopyridines is very similar.
Pharmacokinetics, Drug Metabolism, and Safety of Prasugrel and Clopidogrel
  • S. Achar
  • Biology, Chemistry
    Postgraduate medicine
  • 2011
TLDR
An overview of the pharmacokinetics of prasugrel and clopidogrel is provided and factors that would influence the metabolism of those drugs are discussed and it is suggested that more patients will receive adequate platelet inhibition after administration of pr asugrel.
Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping index.
TLDR
The disposition of 8, 14-dihydroxy-EFV appears to be sensitive to CYP2B6 activity alterations in human subjects and the 8,14-dhydroxyefaviremz : efavirenz AUC(0,120 h) ratio is attractive as a candidate phenotyping index for CYP6 activity in vivo.
Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine.
TLDR
The inhibitory effects of all the compounds tested were much weaker on the isoforms other than those indicated above, and the active metabolites of clopidogrel and prasugrel and clopIDogrel acid metabolite also did not affect the activities of the P450s examined.
...
...

References

SHOWING 1-10 OF 27 REFERENCES
Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine
TLDR
Inhibition of CYP2B6 was time- and concentration-dependent, and as shown by dialysis experiments, it was irreversible and dependent on NADPH, suggesting a mechanism-based mode of action, and the possibility of drug interactions between thienopyridine derivates and drug substrates of CYp2B 6 and CYP1A2 is suggested.
Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19.
TLDR
Ticlopidine is the first selective mechanism-based inhibitor of human liver CYP2C19 and should be a new interesting tool for studying the topology of the active site of CYP 2C19.
Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.
TLDR
Results demonstrate selectivity of BUP hydroxylation for CYP2B6 at 500 microM BUP, thereby validating its use as a diagnostic in vitro marker of CYP 2B6 catalytic activity.
Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation.
TLDR
It is suggested that CYP3A4 does not significantly catalyze BUP hydroxylation, and this results complement recent data supporting selectivity of B UP hydroxymation for CYP2B6 at 500 microM BUP.
Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro.
TLDR
ThioTEPA is a drug of choice when high CYP2B6 selectivity among major P450 enzymes is required and ticlopidine is a useful alternative under a controlled experimental setup and when higher potency is needed.
CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.
TLDR
Bupropion hydroxylation is mediated almost exclusively by CYP2B6 and can serve as an index reaction reflecting activity of this isoform and suggest a low inhibitory potency versus CYP 2D6, the clinical importance of which is not established.
The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and clinical developments
TLDR
Clopidogrel appears to offer several advantages over ticlopidine: a more rapid onset of action and a lower incidence of neutropenia and thrombotic thromBocytopenic purpura.
Carbamazepine but not valproate induces bupropion metabolism.
TLDR
Differential effects of CBZ and VPA on BUP pharmacokinetics influence the tolerability and efficacy of combination therapies with these agents are determined.
...
...